Codexis is a leading synthetic biology company that applies its proprietary CodeEvolver® protein engineering technology to develop proteins for a variety of applications, including as biotherapeutics and for use in drug manufacture and molecular diagnostics. This proven technology enables improvements in protein performance towards meeting the patients' needs for effective therapeutics. Our lead program is CDX-6114, an orally-administrable, GI-stable enzyme for potential treatment of PKU; CDX-6114 is currently in Phase I clinical trials and licensed to Nestlé Health Science. Our discovery pipeline consists of eight programs, including three enzyme candidates for potential treatment of Lysosomal Storage Disorders.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
CDX-6114 for PKU
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):